Scarica l'app Stockscreener
28.01
1.79%
-0.51
Dopo l'orario di chiusura:
27.66
-0.35
-1.25%
Precedente Chiudi:
$28.52
Aprire:
$28.48
Volume 24 ore:
1.82M
Relative Volume:
1.32
Capitalizzazione di mercato:
$3.18B
Reddito:
$4.02M
Utile/perdita netta:
$-224.59M
Rapporto P/E:
-11.77
EPS:
-2.3795
Flusso di cassa netto:
$-205.52M
1 W Prestazione:
+2.23%
1M Prestazione:
+26.11%
6M Prestazione:
+26.63%
1 anno Prestazione:
+171.94%
Intervallo 1D:
$27.64
$28.85
Intervallo di 1 settimana:
$26.76
$30.06
Portata 52W:
$8.665
$30.06
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
28.01 | 3.19B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-28 | Iniziato | Barclays | Overweight |
| 2026-02-12 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.95% Stock GainRevenue Miss Report - Vinanet
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
HC Wainwright Issues Negative Forecast for Immunome Earnings - MarketBeat
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM) - The Globe and Mail
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome gets FDA nod for varegacestat NDA, sets PDUFA date for April 2027 - Pluang
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock - MarketBeat
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com - Investing.com South Africa
Immunome director Isaac Barchas sells over $2.1m in shares - Investing.com
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside - TradingView
IMNM Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.15, Implies 38% Upside - TradingView
IMNM Maintains Outperform by Wedbush -- Price Target Raised to $35 - GuruFocus
Immunome stock hits 52-week high at 27.68 USD By Investing.com - Investing.com South Africa
Immunome stock hits 52-week high at 27.68 USD - Investing.com
Immunome Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Evercore Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings - MarketBeat
Immunome, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Immunome director Isaac Barchas reports disposal of common shares worth $2.18 million - Bitget
IMNM SWOT Analysis: Positive Pipeline Developments Amidst Financ - GuruFocus
Immunome reports $73.1m Q2 loss as FDA accepts varegacestat NDA - scanx.trade
Oncology firm Immunome's Q2 net loss widens as R&D costs rise - TradingView
Immunome (IMNM) widens losses as it funds oncology pipeline with $520M cash - Stock Titan
Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary - TradingView
Immunome reports Q2 2026 net loss $73.1M, cash and marketable securities $520.0M - TradingView
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMNM: FDA accepted NDA for varegacestat; Q2 net loss $73.1M, cash $520M, pipeline advancing - TradingView
Immunome: Expect Current Cash Position to Fund Ops Into 2028 >IMNM - Moomoo
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
California State Teachers Retirement System Has $2.44 Million Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Aug 12 '26 |
Sale |
27.25 |
11,048 |
301,058 |
92,211 |
| Barchas Isaac | Director |
Aug 10 '26 |
Sale |
26.07 |
10,125 |
263,959 |
62,291 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):